Datapoint: FDA Approves Biogen’s Lucentis Biosimilar

The FDA on Monday approved Biogen and Samsung Bioepis’ Byooviz, a biosimilar to Roche’s blockbuster eye drug Lucentis. The approval marks Samsung Bioepis’ fifth biosimilar win. For the treatment of age-related macular degeneration, Lucentis holds covered or better status for 49% of all insured lives under the pharmacy benefit. It is not covered for 30.6% of lives.

SOURCE: MMIT Analytics, as of 9/22/21

0 Comments

AIS Health Staff

Related Posts

https://www.mmitnetwork.com/wp-content/uploads/2021/09/wordpress-featured-image-datapoints.jpg
December 8

Datapoint: Aetna-Allina Health Launch New Plan Designs in Minnesota

Read More
https://www.mmitnetwork.com/wp-content/uploads/2021/09/wordpress-featured-image-datapoints.jpg
December 7

Datapoint: Oklahoma Medicaid Rolls Top 1M After Expansion

Read More
https://www.mmitnetwork.com/wp-content/uploads/2021/09/wordpress-featured-image-datapoints.jpg
December 6

Datapoint: Blue Cross and Blue Shield of Montana Plots Medicare Expansion

Read More

GAIN THERAPEUTIC AREA-SPECIFIC INTEL TO DRIVE ACCESS FOR YOUR BRAND

Sign up for publications to get unmatched business intelligence delivered to your inbox.

subscribe today